OmniHealth Media Announces Opportunity for Polycythemia Vera Patients to Provide Important Insight to Improve Outcomes

OmniHealth Media Announces Opportunity for Polycythemia Vera Patients to Provide Important Insight to Improve Outcomes

Sun Valley, Idaho and Fort Worth, Texas – OmniHealth Media announces the opportunity for polycythemia vera patients to share treatment experience and insight about current and future treatment of PV. Individuals with PV in the US who have been treated by an oncologist or hematologist with either Hydrea or phlebotomy are eligible to participate in this important market research study. The survey will take approximately 20 minutes and qualified individuals who complete the survey will receive a $30 for their time and insight. To learn more, click here.

Polycythemia vera is a type of blood cancer known as a myeloproliferative neoplasm. It involves the abnormal development and function of bone marrow cells that produce blood cells, and leads to the overproduction of red blood cells. White blood cells and platelets may also be overproduced. There is currently no cure for polycythemia vera, but the condition can often be managed for many years and the recent FDA approval of Jakafi® is expanding treatment options. In rare cases, polycythemia vera may progress to myelofibrosis (scarring of the bone marrow) or acute myeloid leukemia (AML).

For more of the latest information on PV, visit the PV Information Center.

LEARN MORE ABOUT PV

Contact:
Charles H. Weaver, MD
chweaver@omnihealthmedia.com

About OMNI Health Media:
OMNI Health Media (OMNI) is a leading specialty website developer and publisher of consumer health information. By incorporating content expertise with social media and web-based programming, OMNI is uniquely qualified to develop and distribute multi-media health education content and social media programming for a variety of health conditions.

Originally established in 1996 as a cancer patient education resource, OMNI has consistently expanded its platform by integrating technologic advances with its health information content, applications and services. OMNI has been recognized for producing award-winning, multi-media content which reaches over 1.5 million health information seekers in English, Japanese, and Spanish every month. OMNI currently produces Web applications and health content in oncology, urology, rheumatology, and women’s health.

The mission of OMNI Health Media is to connect individuals with the most current, comprehensive health information and with others in similar situations. OMNI uses a variety of platforms including online, print, video, social media, and live interactive Web chats to connect and empower individuals to better manage their health conditions.

OMNI Health Media produces and manages Women magazine, CancerConnect.com, TheRAConnection.com, aWomensHealth.com, theGIConnection.com, and The Web Chats with the Experts interactive series featuring thought leaders from institutions such as Memorial Sloan Kettering, Johns Hopkins, Yale, and other prominent health centers.

OMNI content and programming has been independently reviewed by multiple physician practices and hospitals, and endorsed by the National Patient Advocate Foundation and the Oncology Nursing Society. Furthermore, CancerConnect.com has been awarded with the World Wide Web Health Awards’ Gold Award for patient education and information excellence. The Gold Award is the highest possible award bestowed on such sites. CancerConnect.com was named one of the top 5 oncology websites by Oncology Net Guide. Perhaps the biggest vote of confidence for OMNI content and programming is the fact that it has been used by over 250 hospitals, clinics, and advocacy groups including Dana-Farber Cancer Institute, The Susan Komen Foundation, Memorial Sloan-Kettering, Roswell Park and leading physician practices and networks like The West Clinic, Texas Oncology, and other leading community practices from coast to coast. Currently, over 2,700 physicians use OMNI Health Media content programming on their websites.